1. Home
  2. PVH vs EWTX Comparison

PVH vs EWTX Comparison

Compare PVH & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PVH Corp.

PVH

PVH Corp.

N/A

Current Price

$76.21

Market Cap

3.6B

ML Signal

N/A

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

N/A

Current Price

$44.03

Market Cap

3.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PVH
EWTX
Founded
1881
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.7B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
PVH
EWTX
Price
$76.21
$44.03
Analyst Decision
Buy
Buy
Analyst Count
16
6
Target Price
$90.53
$39.00
AVG Volume (30 Days)
864.3K
1.2M
Earning Date
06-03-2026
05-07-2026
Dividend Yield
0.16%
N/A
EPS Growth
N/A
N/A
EPS
1.90
N/A
Revenue
$8,950,200,000.00
N/A
Revenue This Year
$1.89
N/A
Revenue Next Year
$1.86
N/A
P/E Ratio
$41.32
N/A
Revenue Growth
3.44
N/A
52 Week Low
$59.60
$13.69
52 Week High
$100.75
$48.40

Technical Indicators

Market Signals
Indicator
PVH
EWTX
Relative Strength Index (RSI) 43.83 53.34
Support Level $69.08 $41.98
Resistance Level $79.95 $45.48
Average True Range (ATR) 2.56 1.99
MACD -0.73 -0.14
Stochastic Oscillator 24.19 43.45

Price Performance

Historical Comparison
PVH
EWTX

About PVH PVH Corp.

PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, roughly 1,400 standalone stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: